

Clinical Observation on 50 Cases of Advanced Gastric Carcinoma Treated with *Shenling Baizhu Powder* (参苓白术散) Combined TS Chemotherapy Regimen

LI Zhipeng¹, XU Li², XUE Tian², LIU Shenlin², LIN Xuan²

(1. Jiangsu Cancer Hospital, Nanjing, Jiangsu, 210009; 2. The Affiliated Hospital of Nanjing University of Chinese Medicine)

ABSTRACT Objective To observe the clinical effect of *Shenling Baizhu Powder* combined with chemotherapy regimen of paclitaxel liposome + Tegafur Gimeracil Otera (TS regimen) in the treatment of advanced gastric carcinoma.

Methods One hundred patients with advanced gastric carcinoma were randomly divided into a treatment group and a control group, with 50 cases in each group. The control group was given chemotherapy with TS regimen that was intra-venous drip with paclitaxel liposome, 75 mg/m² on the 1st day and the 8th day, and oral administration of Tegafur Gimeracil Otera capsule, 80 mg/m² from the 1st day to the 14th day, once in the morning and once at night. The regimen took 14 days as one cycle, and totally four cycles of treatment were given. Two days before each chemotherapy cycle, the treatment group started to take modified *Shenling Baizhu Powder*, one dose daily, for 12 days during chemotherapy, totally for four cycles. Short-term effects, quality of life, and incidence of adverse reactions were compared between the two groups after the chemotherapy. **Results** There was no statistically significant difference in the total effective rate and the clinical benefit rate of short-term effects between two groups ($P > 0.05$). The total improvement rate of quality of life was 50% in the treatment group, and 36% in the control group. The quality of life in the treatment group was better than that in the control group ($P < 0.05$). After treatment, there were significant differences in incidence of nausea, vomiting, diarrhea, and pain between the two groups ($P < 0.05$), and those in the treatment group were significantly lower than those in the control group. After treatment, there were no significant differences in incidence of myelosuppression and hepatic function damage between the two groups ($P > 0.05$). **Conclusion** *Shenling Baizhu Powder* combined with TS chemotherapy regimen can improve quality of life of the patients with advanced gastric carcinoma and reduce the incidence of adverse reactions from chemotherapy.

Keywords advanced gastric carcinoma; *Shenling Baizhu Powder* (参苓白术散); TS regimen; quality of life; adverse reactions

(收稿日期: 2015-10-11; 修回日期: 2016-05-16)

编辑: 侯建春

2016 年中国女性健康阳光论坛通知

为推动女性疾病的交流与学术发展,增进妇科、乳腺外科、皮肤科工作者的学术交流,展现并分享业内专家在女性疾病的中医临床特色治疗及基础科研领域的成果,由北京中医药大学第三附属医院、中国中医科学院教育处和中医杂志社主办的“2016 中国女性健康阳光论坛”定于 2016 年 8 月 20-21 日在北京举行。

一、论坛内容: 涵盖妇科、乳腺外科、皮肤科等学科领域,既有最新进展,又有特色中医治疗,既有大师级讲者,又有临床教授授课,学术内容丰富实用。二、论坛形式: 1. 特邀演讲: 邀请妇科、乳腺外科、皮肤科等学科领域确有真知灼见的名家通过 30~40 分钟授课与交流,使论坛真正成为名师传道授业解惑的平台。2. 疑难点讨论: 将选择妇科、乳腺外科、皮肤科等某一常见疑难困惑问题,在专家答疑基础上,让与会者广泛讨论。3. 疑难病例分享: 典型中医药治疗的有效病例,有思路、有新方法,通过对病例精细入微的分析,让与会者分享中医药治疗妇科、乳腺外科、皮肤科等学科及其疑难病症真真切切的效果。三、部分专家介绍: 王庆国,主任医师、教授,国家级名老中医,北京中医药大学原副校长、师从著名中医药学家刘渡舟教授,国家首批学术流派之首——燕京刘氏伤寒学派负责人。裴晓华,主任医师,北京中医药大学第三附属医院外科教研室主任、中华中医药学会外科分会主任委员、中国中医药研究促进会乳腺病分会主任委员。杨志波,主任医师,湖南中医药大学第二附属医院皮肤科主任,国家中医药管理局皮肤免疫病理科研三级实验室主任,湖南中医药大学第二附属医院中医外科教研室主任。李元文,主任医师,北京中医药大学东方医院副院长,皮科学科带头人,长期从事皮肤性病的医疗和教学。鲍身涛,北京中医药大学第三附属医院皮肤科主任,从事皮肤病性病专业研究和诊治工作 20 余年。杜惠兰,主任医师,河北医科大学中西医结合学院院长、中华中医药学会妇科分会副主任委员、中国医师协会中西医结合医师协会理事。连方,主任医师、生殖中心主任,中华中医药学会妇科专业委员会副主任委员、中国中西医结合学会妇产科专业委员会副主任委员。赵瑞华,中国中医科学院广安门医院主任医师,对妇科疑难病有深入研究。沈冬,主任医师,中国中医科学院广安门医院皮肤科湿疹组组长,重点专科湿疹学科带头人。张广中,北京中医医院主任医师,世界中医药学会联合会皮肤科分会常务理事,对赵炳南学术思想和经方治疗皮肤病的规律有深入研究。马小娜,副主任医师,北京中医药大学第三附属医院妇科主任,师从国家级名老中医王庆国教授,世界中医药学会联合会仲景分会理事。四、会议地址: 北京西藏大厦(北京朝阳区北四环东路 118 号,安慧桥东,电话: 010-64981133),标准间 460 元/天。会务费: 600 元/人。银行汇款: 账户名: 北京东方岐黄科技服务中心,账号: 0200004309024515428,开户行: 工商银行北京北新桥支行。收费联系电话: (010) 64089182。五、联系人: 贾守凯(13901318324),江涛(13811379689),张宇(18911259118)。详情请登录《中医杂志》网站 www.jtcm.net.cn 查询。微信公众号: zyzgzh。E-mail: A64089192@126.com。